Details

Chiral switch of a butyrylcholinesterase inhibitor for the treatment of Alzheimer's disease
ID Košak, Urban (Author), ID Knez, Damijan (Author), ID Ferjančič Benetik, Svit (Author), ID Mastnak-Sokolov, Peter (Author), ID Pišlar, Anja (Author), ID Horvat, Selena (Author), ID Stojan, Jure (Author), ID Gobec, Stanislav (Author), et al.

.pdfPDF - Presentation file, Download (6,28 MB)
MD5: 391971EEC34DB34AF1CDF90BC9F11E79
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S000927972500300X This link opens in a new window

Abstract
Butyrylcholinesterase (BChE) is a viable drug target to alleviate the symptoms of Alzheimer's disease (AD). We recently developed and biologically evaluated racemic N-benzylpiperidine-based naphthalene-2-sulfonamide 2, a nanomolar BChE inhibitor with procognitive effects. To optimize it, we performed a chiral switch. Using semi-preparative chiral HPLC, we isolated the pure enantiomers (R)-(−)-2 and (S)-(+)-2 and confirmed that (R)-(−)-2 is the eutomer and (S)-(+)-2 is the distomer with respect to human (h)BChE inhibition. Notably, (R)-(−)-2 is a less potent inhibitor of human acetylcholinesterase (hAChE) than both racemate 2 and (S)-(+)-2, which is advantageous, since AChE inhibition is associated with undesirable peripheral parasympathomimetic adverse effects. The crystal structures of hBChE in complexes with each enantiomer revealed distinct binding poses. The crystal structure of hBChE in complex with (R)-(−)-2 confirmed our previous hypothesis that only the (R)-(−)-2 is bound in the active site of hBChE when the racemate is crystallized. The synthesis of (R)-2 hydrochloride has a higher overall yield (73 %) than the synthesis of racemate 2 hydrochloride (64 %) and is safer as it avoids the use of LiAlH$_4$. (R)-(−)-2 has in vivo efficacy in mice with scopolamine-induced AD-like symptoms, and (R)-(−)-2 is less toxic in mice LD$_{50}$ = 169 mg/kg) than racemate 2 LD$_{50}$ = 112 mg/kg). These results support the chiral switch from racemate 2 to (R)-(−)-2 as a safer and more selective lead compound in the anti-AD drug development pipeline.

Language:English
Keywords:chiral switch, resolution of enantiomers, Alzheimer's disease, butyrylcholinesterase, enzyme inhibitors
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2025
Number of pages:15 str.
Numbering:Vol. 420, art. 111670
PID:20.500.12556/RUL-175877 This link opens in a new window
UDC:616.894
ISSN on article:0009-2797
DOI:10.1016/j.cbi.2025.111670 This link opens in a new window
COBISS.SI-ID:250780931 This link opens in a new window
Publication date in RUL:12.11.2025
Views:467
Downloads:243
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Chemico-biological interactions
Shortened title:Chem.-biol. interact.
Publisher:Elsevier
ISSN:0009-2797
COBISS.SI-ID:1720335 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:kiralno stikalo, ločljivost enantiomerov, butirilholinesteraza, encimski zaviralci, Alzheimerjeva bolezen

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P4-0127
Name:Farmacevtska biotehnologija: znanost za zdravje

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:N1-0277
Name:Raziskave multifunkcionalnih spojin, usmerjenih proti nevroinflamaciji in holinergičnemu pomanjkanju pri Alzheimerjevi bolezni

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:BI-FR/23-24-PROTEUS-002
Name:Razvoj učinkovitih reaktivatorjev z organofosfati zavrte butirilholin esteraze

Funder:ARIS - Slovenian Research and Innovation Agency
Funding programme:Univerza v Ljubljani
Project number:SN-ZRD/22-27/0510

Funder:France, Ministry of Armed Forces
Project number:NBC-5-C-2316

Funder:China
Funding programme:Central and Eastern European countries University joint education program
Project number:2022248

Funder:China
Funding programme:Central and Eastern European countries University joint education program
Project number:2023282

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back